Despite the significance of immune checkpoint inhibitors (ICIs) in solid tumor treatment, identifying ICI-sensitive populations remains a challenge.
Mutations in DNA damage response (DDR) pathway genes are increasingly linked to favorable ICI responses; however, selection criteria for specific DDR pathway biomarkers remain elusive.
